Amgen’s heart drug reduces cardiovascular disease risk factor in phase 2 trial
Amgen’s heart drug reduces cardiovascular disease risk factor in phase [...]
BioMarin’s hemophilia A gene therapy further delayed amid new FDA questions
BioMarin’s hemophilia A gene therapy further delayed amid new FDA [...]
Sanofi’s Hemlibra rival gets step closer to approval with FDA breakthrough tag
Sanofi’s Hemlibra rival gets step closer to approval with FDA [...]
After Axsome’s migraine med rejection, phase 3 data keeps hope alive for depression drug
After Axsome’s migraine med rejection, phase 3 data keeps hope [...]
After oncology wind-down, TG’s pivot to MS faces setback as FDA pushes approval decision
After oncology wind-down, TG’s pivot to MS faces setback as [...]
Bouncing back from late-phase fail, Minoryx pockets €51M to guide rare disease drug to market
Bouncing back from late-phase fail, Minoryx pockets €51M to guide [...]
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight KRAS battle
ASCO: Mirati cedes to Amgen’s Lumakras on durability in tight [...]
Addex’s eyelid data fail to make clear case for spasm expansion
Addex’s eyelid data fail to make clear case for spasm [...]
Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anyway
Iovance sinks 50% as pivotal cell therapy data disappoint investors, [...]
ASCO: Genentech touts bispecific data for DLBCL, calling it ‘groundbreaking’ for heavily pretreated patients
ASCO: Genentech touts bispecific data for DLBCL, calling it ‘groundbreaking’ [...]